Indeed, in the last few decades, the drug-targetable property of THRs has been utilized to develop different THRβ selective modulators (Figure 1) to treat primarily lipid-related metabolic disorders, including dyslipidemia and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) [19,20,21,22,23,24,25,26,27]. Here, THRB is linked to metabolic dysfunction-associated steatotic liver disease.